<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B2367618-D94D-43F8-A5DA-FA05109669DD"><gtr:id>B2367618-D94D-43F8-A5DA-FA05109669DD</gtr:id><gtr:name>Epix Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Cell Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B2367618-D94D-43F8-A5DA-FA05109669DD"><gtr:id>B2367618-D94D-43F8-A5DA-FA05109669DD</gtr:id><gtr:name>Epix Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/78A0D09E-1EE0-4E82-8BB3-DBAEB2CDEE28"><gtr:id>78A0D09E-1EE0-4E82-8BB3-DBAEB2CDEE28</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Mitcheson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0001361"><gtr:id>4C8C5B76-7FF7-44F6-9C05-49F191492A5C</gtr:id><gtr:title>The Molecular Basis of Gating &amp;amp; High Affinity Drug Block of HERG Potassium Channels Associated with Cardiac Arrhythmia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0001361</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>379706</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bologna (Universit? di Bologna UNIBO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Pharmacy and Biotechnology (FaBiT)</gtr:department><gtr:description>Collaboration with Prof Recanatini</gtr:description><gtr:id>3DBDBC95-9A65-4C97-85F3-5F9668352B1A</gtr:id><gtr:impact>22455383</gtr:impact><gtr:partnerContribution>Performed computational modelling and analysis</gtr:partnerContribution><gtr:piContribution>Provided technical expertise and performed electrophysiology experiments. Has resulted in a publication. 22455383</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Drug Safety and Metabolism Externalisation</gtr:department><gtr:description>Astrazeneca collaboration</gtr:description><gtr:id>7F5E29CF-277A-425D-AA56-8D70A538E9FC</gtr:id><gtr:impact>This collaboration enabled our collaborators to establish
assays and knowhow
that have been valuable in their
research. The collaboration resulted in a publication 15574182</gtr:impact><gtr:partnerContribution>Provided funding, reagents, infrastructure, and day to day supervision of Postdoctoral research assistant</gtr:partnerContribution><gtr:piContribution>We provided training in experimental techniques. We
guided the direction of the project and the experimental
design</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HERG channel gating and pharmacology.</gtr:description><gtr:id>9791F132-BA46-40D8-83BF-3620D967F382</gtr:id><gtr:impact>The collaboration resulted in a student gaining her PhD. One manuscript with support from this collaboration has been published - 17823114. Two other publications are in the pipeline.</gtr:impact><gtr:partnerContribution>They gave us access to automated patch clamp equipment and consumables that enabled us to do experiments that would otherwise have been unfeasible.</gtr:partnerContribution><gtr:piContribution>We have provided expertise and experimental know-how that has guided their research</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>hERG potassium channel pharmacology</gtr:description><gtr:id>3B5E7961-5DBA-4A5A-A255-168DEE5E0720</gtr:id><gtr:impact>This collaboration enabled our collaborators to establish assays and know-how that have been valuable in their research. The collaboration resulted in a publication - 15574182</gtr:impact><gtr:partnerContribution>Provides additional resources for research and discussions have been useful for guiding current and potential future projects</gtr:partnerContribution><gtr:piContribution>We provided training in experimental techniques. We guided the direction of the project and the experimental design</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epix Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>EPIX contract research</gtr:description><gtr:id>C480F37C-9C89-414A-9D80-FE1F4D325E75</gtr:id><gtr:impact>It provided research income to fund other basic science projects and equipment for the lab.
Outcomes are subject to confidentiality agreements</gtr:impact><gtr:partnerContribution>Provided funding and compounds to be tested</gtr:partnerContribution><gtr:piContribution>We investigated the drug interactions with ion channels</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>A chimeric approach to investigating drug binding in HERG channels.</gtr:description><gtr:id>26FA1DAB-33CC-4A8F-A2FA-C44F710B8478</gtr:id><gtr:impact>The collaboration resulted in a student gaining his PhD. There are publications in the pipeline. Further funding support from Novartis also resulted from this collaboration.</gtr:impact><gtr:partnerContribution>They have provided resources and access to equipment that have facilitated our research</gtr:partnerContribution><gtr:piContribution>We have provided expertise and experimental know-how that has guided their research</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Work experience for school pupils</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A76F04A8-B17C-49C9-A01E-AC233FCF995C</gtr:id><gtr:impact>A-level pupils spend time in my laboratory and find out more about scientific research and careers

Pupils motivated to go to University and consider research careers</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2010,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited seminars at academic institutions</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A86258B4-DDDC-49EB-80E4-4A27C99F1ECB</gtr:id><gtr:impact>One hour seminars followed by discussions with primary investigators at academic institutions

Helped with setting up of collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>17864888-5E6E-47E2-9DDA-EC89EB847852</gtr:id><gtr:impact>Public open days. Ran practical demonstrations for public on the electrocardiogram, spirometer and other physiological functions. Discussed research with interested members of the public

Generated considerable interest in local community</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCAS day demonstrations</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A70F3BD-E6D4-4289-BDB5-F66E2DECBCAB</gtr:id><gtr:impact>Groups of 20+ school pupils attend demonstrations and workshops of physiology experiments. Engaged children in subject of physiology and encouraged them to consider scientific career.

Engaged pupils and encouraged them to do University degree.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Symposium presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CF534C7E-6103-4A84-BCC2-7EDB399E587C</gtr:id><gtr:impact>I have given several research presentations to mixed audiences of academics and industry scientists

Helped with the setting up of collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novartis/MRC CASE PhD studentship</gtr:description><gtr:end>2006-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4A852A82-4932-474E-922E-EC4B8E9642CF</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2003-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novartis MRCCASE PhD Studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5F144EE6-4E59-45C6-B5A8-9FC0737ED55F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>146188</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project Grant</gtr:description><gtr:end>2008-08-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>99DF435B-BE8D-41FD-A7AA-860062276445</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Generated plasmid constructs and hERG and hEAG channel mutants</gtr:description><gtr:id>AB42F68C-7F98-4E33-A915-892A110C81F8</gtr:id><gtr:impact>Used as research materials by several collaborators</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>molecular biology reagents</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Developed and improved in-silico models of hERG potassium channels for investigating drug induced long QT syndrome</gtr:description><gtr:id>3D049876-E6A2-4281-9312-88F814B03AAD</gtr:id><gtr:impact>Significantly enhanced our understanding of drug-induced long QT syndrome. Also very useful tool for developing new hypotheses. Used by pharmaceutical companies in drug development</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>In-silico model of hERG potassium channel</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BAA475BE-EA8E-4498-A66B-0CA4269FDCA3"><gtr:id>BAA475BE-EA8E-4498-A66B-0CA4269FDCA3</gtr:id><gtr:title>Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a997533f4ecb6c8471d05cbdaa7092b0"><gtr:id>a997533f4ecb6c8471d05cbdaa7092b0</gtr:id><gtr:otherNames>Cockerill SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4902D0F8-3F9C-4905-9B9D-1E51AEFEAA40"><gtr:id>4902D0F8-3F9C-4905-9B9D-1E51AEFEAA40</gtr:id><gtr:title>Molecular determinants of HERG channel block.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78220c8a07be9401a0e7398d117a0f9a"><gtr:id>78220c8a07be9401a0e7398d117a0f9a</gtr:id><gtr:otherNames>Kamiya K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E9FFD88-2DBB-4C4A-AE61-47330AE15FB6"><gtr:id>8E9FFD88-2DBB-4C4A-AE61-47330AE15FB6</gtr:id><gtr:title>Insight into the mechanism of inactivation and pH sensitivity in potassium channels from molecular dynamics simulations.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a807eff7a6f8b2dc6e13baea9674e0a"><gtr:id>5a807eff7a6f8b2dc6e13baea9674e0a</gtr:id><gtr:otherNames>Stansfeld PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03EE442A-EA28-426B-B821-7DBB63B7B0E9"><gtr:id>03EE442A-EA28-426B-B821-7DBB63B7B0E9</gtr:id><gtr:title>Long-term channel block is required to inhibit cellular transformation by human ether-&amp;agrave;-go-go-related gene (hERG1) potassium channels.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8b6388794327fe010364f5980d3256a3"><gtr:id>8b6388794327fe010364f5980d3256a3</gtr:id><gtr:otherNames>Pier DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/306CC254-6FAF-469A-8618-DA236668A619"><gtr:id>306CC254-6FAF-469A-8618-DA236668A619</gtr:id><gtr:title>Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2939dd3cfb2744e4070fdb2bdc098444"><gtr:id>2939dd3cfb2744e4070fdb2bdc098444</gtr:id><gtr:otherNames>Hancox JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5E37C084-BF7B-41CD-9FD2-154F86C3FF4E"><gtr:id>5E37C084-BF7B-41CD-9FD2-154F86C3FF4E</gtr:id><gtr:title>Direct block of human ether-a-go-go-related gene potassium channels by caffeine.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a997533f4ecb6c8471d05cbdaa7092b0"><gtr:id>a997533f4ecb6c8471d05cbdaa7092b0</gtr:id><gtr:otherNames>Cockerill SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ADB5CE74-473D-46E0-B946-AB69A0D2CD1E"><gtr:id>ADB5CE74-473D-46E0-B946-AB69A0D2CD1E</gtr:id><gtr:title>Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/684d519b281f7bba168e6185fd08414b"><gtr:id>684d519b281f7bba168e6185fd08414b</gtr:id><gtr:otherNames>Perry M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9C145C3-2BFB-4F46-A668-2444FE1449AD"><gtr:id>F9C145C3-2BFB-4F46-A668-2444FE1449AD</gtr:id><gtr:title>Activation gating of hERG potassium channels: S6 glycines are not required as gating hinges.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9a6a14e900fb5f441a444114d58eaacf"><gtr:id>9a6a14e900fb5f441a444114d58eaacf</gtr:id><gtr:otherNames>Hardman RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/699C2CDD-D2AF-4D28-A4B6-0C6548311D62"><gtr:id>699C2CDD-D2AF-4D28-A4B6-0C6548311D62</gtr:id><gtr:title>Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug metabolism &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a807eff7a6f8b2dc6e13baea9674e0a"><gtr:id>5a807eff7a6f8b2dc6e13baea9674e0a</gtr:id><gtr:otherNames>Stansfeld PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1742-5255</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1C41F4FA-C581-4406-88D9-7C8BC518B3D2"><gtr:id>1C41F4FA-C581-4406-88D9-7C8BC518B3D2</gtr:id><gtr:title>Drug block of the hERG potassium channel: insight from modeling.</gtr:title><gtr:parentPublicationTitle>Proteins</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a807eff7a6f8b2dc6e13baea9674e0a"><gtr:id>5a807eff7a6f8b2dc6e13baea9674e0a</gtr:id><gtr:otherNames>Stansfeld PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0887-3585</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EFDB232-4065-4F62-A056-CE1EEC42369E"><gtr:id>3EFDB232-4065-4F62-A056-CE1EEC42369E</gtr:id><gtr:title>Revealing the structural basis of action of hERG potassium channel activators and blockers.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/684d519b281f7bba168e6185fd08414b"><gtr:id>684d519b281f7bba168e6185fd08414b</gtr:id><gtr:otherNames>Perry M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FEC871DD-F687-4261-BC24-BDB00C288A3A"><gtr:id>FEC871DD-F687-4261-BC24-BDB00C288A3A</gtr:id><gtr:title>hERG potassium channels and the structural basis of drug-induced arrhythmias.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/981e004564c196aa4d85467b1c6d81dc"><gtr:id>981e004564c196aa4d85467b1c6d81dc</gtr:id><gtr:otherNames>Mitcheson JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0001361</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>